In addition, VSV-S treatment lowered PD-L1 expression on tumor cells and, when combined with anti-PD-1 immune checkpoint blockade, produced synergistic antitumor efficacy, greater tumor suppression, and survival benefit than either treatment alone [81]. This evidence concerns the gene CD274 and neoplasm.